February 23, 2021
1 min read
Syed K, et al. Paper 14. Presented at: Lumbar Spine Research Society Annual Meeting; Nov. 12-15, 2020 (virtual meeting).
Disclosures: Parola reports no relevant financial disclosures.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
ADDED TO EMAIL ALERTS
We were unable to process your request. Please try again later. If you continue to have this issue please contact email@example.com.
Back to Healio
Use of bone morphogenetic protein in single-level lumbar fusion may have a higher risk profile than previously reported with non-significant benefits, according to results.
Rown Parola, MS, and colleagues categorized 362,530 Medicare patients who underwent single-level lumbar fusion between 2004 and 2014 into groups based on whether they received bone morphogenetic protein (BMP).
“The demographics and comorbidities were also identified by ICD-9 diagnosis code, and then we underwent propensity matching, trying to match our cohorts along the basis of age, Elixhauser comorbidity index, sex, region, treatment year, smoking status, osteoporotic status and nutritional status,” Parola said in his presentation at the Lumbar Spine Research Society Annual Meeting…